Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Apitegromab: Phase 3 SAPPHIRE in SMA# The Phase 3 SAPPHIRE trial represents the most advanced clinical success for any myostatin-targeted therapy: 188 patients aged 2-21 with Type 2 or 3 SMA, all receiving background SMN-targeted treatment Primary endpoint met : Clinically meaningful improvement on HFMSE (Hammersmith Functional Motor Scale Expanded) versus placebo (p=0.0192), with a mean difference of 1.8 points Functional responders : 30.4% of apitegromab patients achieved 3 or more point HFMSE improvement versus 12.5% placebo Upper limb function : Consistent improvement measured by RULM (Revised Upper Limb Module) Published in The Lancet Neurology This is notable because it overcomes the historical "mass-function disconnect" that plagued earlier myostatin inhibitors -- apitegromab improved actual motor function, not just muscle mass
2) 23,24 , suggesting they play a similar role in monotremes
Taken together, mitochondrial abnormalities are closely associated with synaptic aberrations, including impaired synaptic transmission, in various ASD-related syndromes of genetic origin (Table 2)
Does clear and brilliant help acne scars
US$ 26.31
US$ 22.58
US$ 25.29
US$ 24.18
US$ 25.58
US$ 24.40
US$ 28.66
US$ 22.94
US$ 22.82
